In a report released today, Salim Syed from Mizuho Securities maintained a Buy rating on Amgen Inc (AMGN), with a price target of $208. The company’s shares closed yesterday at $169.92, close to its 52-week low of $166.30.
According to TipRanks.com, Syed has currently no stars on a ranking scale of 0-5 stars, with an average return of -4.0% and a 39.2% success rate. Syed covers the Healthcare sector, focusing on stocks such as Unity Biotechnology Inc, Atara Biotherapeutics, and Wave Life Sciences.
Currently, the analyst consensus on Amgen Inc is a Moderate Buy with an average price target of $212.33, representing a 25.0% upside. In a report issued on May 15, Cowen & Co. also maintained a Buy rating on the stock with a $229 price target.
See today’s analyst top recommended stocks >>
Amgen Inc’s market cap is currently $104.4B and has a P/E ratio of 13.55. The company has a Price to Book ratio of 9.64.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
